Insomnia in Elderly Patients: Recommendations for Pharmacological Management

This review focuses on Food and Drug Administration -approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs, benzodiazepines, and ramelteon

Vivien C. Abad

2018

Scholarcy highlights

  • Chronic insomnia affects 57% of the elderly in the United States, with impairment of quality of life, function, and health
  • This review focuses on Food and Drug Administration-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs, benzodiazepines, and ramelteon
  • We review the indications, dosing, efficacy, benefits, and harms of these drugs in the elderly, and discuss data on drugs that are commonly used off-label to treat insomnia, and those that are in clinical development
  • Eszopiclone or zolpidem extended release can be utilized for both sleep onset and sleep maintenance
  • Questions and answers on the withdrawal of the marketing application for Ramelteon

Need more features? Save interactive summary cards to your Scholarcy Library.